Skip to main content
MSF logo
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Media room
  • Contact
  • msf.org
  • MSF Access
    • About MSF Access
    • Media room
    • Latest news
    • Jobs
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Our work
    • Diabetes
    • Drug-resistant infections
    • Hypertension
    • Patents and intellectual property
      • Pandemic prevention, preparedness and response
      • The Patent Oppositions Database
    • Research and development
      • Spotlight on: the Big Pharma double-dip
      • Transparency Matters: Clinical Trials Costs
    • Tuberculosis
    • Vaccines
    • Other work
      • COVID-19
      • Hepatitis C
      • HIV/AIDS
      • Tropical and neglected diseases
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Get involved
    • Campaign success stories
      • #NoMoreTears Johnson & Johnson Can you hear us?
      • A Fair Shot
      • Novartis 'Drop the case'
      • Trans-pacific Partnership (TPP)
    • Recent campaigns
      • Time for $5
      • No Patents in a Pandemic
      • Share the Tech - Save Lives
    MSF Access Missions Medicines Should Not be a Luxury
    Take Action
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
  • Resources
    • Press releases
    • Statements
    • Letters
    • Opinion articles
    • Feature stories
    • Interviews
    • Blog
    • Newsletters
    • Publications
    • Research articles
    • Topic overview pages
    • Videos
    • Photo stories
    • Infographics
    • Events
    Get Involved!
    Sign up to stay updated and find out how you can get involved.
Medicines shouldn’t be a luxury Take action
Get involved
Our campaigns

Latest Press Releases

Latest Press Releases

Press release
Press release |
10 October 2019
Tuberculosis

MSF launches global campaign urging Johnson & Johnson to reduce price of life-saving TB drug

7 min
Close up of sachets of the drug Delamanid in the Town 2 Clinic, Kuyasa, Khayelitsha, Western Cape in South Africa. Photograph by Sydelle WIllow Smith
Press release
Press release |
09 October 2019
Tuberculosis
South Africa

MSF calls for new price of anti TB drug delamanid to be lowered and offered outside of South Africa 

4 min
Doctor Ogembo doing the morning round with clinical officer Winnie at Homa Bay hospital Photograph by Patrick Meinhardt
Press release
Press release |
07 October 2019
HIV/AIDS Malaria Tuberculosis

Urgent boost and ‘reality check’ needed for HIV and TB funding, says new MSF report

"" Photo credit: Mudit Mathur
Press release
Press release |
23 September 2019
Intellectual property and trade
United States of AmericaIndia

MSF urges PM Modi not to make any trade commitments to US threatening access to medicines

MSF logistician, Athanasios Papadopoulos holding a sign advocating for broader use of the pneumonia vaccine at a lower price Photograph by Anna Pantelia
Press release
Press release |
26 August 2019
Vaccines

Gavi should stop awarding special funds to Pfizer and GSK for pneumonia vaccine

5 min
S. Thangkhoshin Hookip is an MDR-TB patient in Churachandpur. Every day, a DOTS nurse visits him to administer an injection and watch him take all the medicine he has to take daily (15 pills in total). The home-based treatment normally lasts around two years. Photograph by Jan-Joseph Stok
Press release
Press release |
14 August 2019
Tuberculosis

Pretomanid - third new TB drug in over half a century must be affordable

Information and education activities during an active Hepatitis C case finding campaign in Cambodia. Photograph by Simon Ming
Press release
Press release |
25 July 2019
Hepatitis C
Cambodia

Cambodia: Simpler and more affordable treatment for hepatitis C saves lives

4 min
Community Health Agent Babongile Luhlongwane is one of nearly 90 dedicated health workers who are taking HIV counseling and testing to the most remote parts of KwaZulu-Natal. Photograph by Greg Lomas
Press release
Press release |
17 July 2019
HIV/AIDS

Fight is not over as AIDS deaths remain high

  • Load More
Navigate
  • About MSF Access
  • Contact us
  • Get involved
  • Our work
  • Resources
  • Search
Get updates
  • Sign up for our newsletter
  • Privacy & data protection information
Contact

MSF Access
Médecins Sans Frontières
140 Route de Ferney
1202 Geneva, Switzerland
Phone:+41 22 849 8484
E-mail: [email protected]

Follow us

  • X
  • Facebook
  • YouTube
  • Medium
Medicines Shouldn't Be A Luxury